Summary of COVID-19 brilacidin studies

1. Innovation Pharmaceuticals et al., A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19

120 patient brilacidin late treatment RCT: no change in mortality (p=1), 33% higher combined mortality/intubation (p=1), and 20% worse recovery (p=1).
RCT 120 hospitalized COVID-19 patients showing no significant differences in pre-defined outcomes with brilacidin.
Jul 2021, Innovation Pharmaceuticals, NCT04784897, https://clinicaltrials.gov/study/NCT04784897, https://c19p.org/ipharm